BGI
FHTX icon

B Group Inc’s Foghorn Therapeutics FHTX Stock Holding History

B Group Inc’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$976K Buy
200,000
+98,000
+96% +$435K 0.46% 19
2026
Q1 		$488K Buy
+102,000
New +$560K 0.36% 18

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

B Group Inc's FHTX Position: Q2 2026 in Review

B Group Inc increased its Foghorn Therapeutics (FHTX) stake by 96% in Q2 2026, buying an estimated $435K and bringing the position to 200,000 shares worth $976K. The position accounts for 0.46% of the portfolio, ranked #19.

B Group Inc first reported a position in FHTX in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • B Group Inc held 200,000 shares of Foghorn Therapeutics worth $976K as of Q2 2026.
  • B Group Inc bought 98,000 Foghorn Therapeutics shares in Q2 2026, an estimated $435K.
  • Foghorn Therapeutics made up 0.46% of B Group Inc's portfolio in Q2 2026, its #19 holding.
  • B Group Inc first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.